Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Feb 2020

Pruis M A, Geurts-Giele W R R, von der Thüsen J H, Meijssen I C, Dinjens W N M, Aerts J G J V, Dingemans A M C, Lolkema M P, Paats M S, Dubbink H J

Abstract excerpt

OBJECTIVES: The oncogenic MET exon 14 skipping mutation (METex14del) is described to drive 1.3 %-5.7 % of non-small-cell lung cancer (NSCLC) and multiple studies with cMET inhibitors show promising clinical responses. RNA-based analysis seems most optimal for METex14del detection, however, acquiring sufficient RNA material is often problematic. An alternative is DNA-based analysis, but commercially available...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crizotinib

Share to Diagnostic Tests, Routine

Share to DNA, Neoplasm

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Share to Survival Rate

Source

Identifiers

PMID: 31862577
DOI: 10.1016/j.lungcan.2019.11.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.PMID 31862577Read ↗

Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective.Semantic proximity Read ↗

Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.Semantic proximity Read ↗

Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach.Semantic proximity Read ↗

Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.Semantic proximity Read ↗

Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.Semantic proximity Read ↗

Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals.Semantic proximity Read ↗

Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.Semantic proximity Read ↗

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutationsSemantic proximity Read ↗

MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels.Semantic proximity Read ↗

Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world studySemantic proximity Read ↗

An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.